MedPacto, Inc.

KOSDAQ 235980.KQ

MedPacto, Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 55.76 M

MedPacto, Inc. Cash and Short-Term Investments is USD 55.76 M for the year ending December 31, 2023, a -27.20% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

MedPacto, Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 76.59 M, a -24.73% change year over year.
MedPacto, Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 101.76 M, a 144.68% change year over year.
MedPacto, Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 41.59 M, a -33.32% change year over year.
MedPacto, Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 62.37 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 235980.KQ

MedPacto, Inc.

CEO	Mr. Seong-Jin Kim
IPO Date	Dec. 19, 2019
Location	South Korea
Headquarters	Borim Building
Employees	57
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.

Key trends

Past 5 years